Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H25ClN2O3.2ClH |
| Molecular Weight | 461.81 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OC(=O)COCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3
InChI
InChIKey=PGLIUCLTXOYQMV-UHFFFAOYSA-N
InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H
| Molecular Formula | C21H25ClN2O3 |
| Molecular Weight | 388.888 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/cetirizine.html
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/cetirizine.html
Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis, hay fever and chronic idiopathic urticaria. Commonly reported adverse reactions of cetirizine include headache, dry mouth and drowsiness or fatigue. Pharmacokinetic interaction studies with Cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. No interactions were observed.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 8.2 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ZYRTEC HIVES RELIEF Approved UseTablets should be administered when both the antihistaminic properties of cetirizine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired. Launch Date1995 |
|||
| Palliative | ZYRTEC HIVES RELIEF Approved UseTablets should be administered when both the antihistaminic properties of cetirizine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired. Launch Date1995 |
|||
| Palliative | ZYRTEC HIVES RELIEF Approved UseUses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •sneezing •itchy, watery eyes •itching of the nose or throat Launch Date1995 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
978.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2571627/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
CETIRIZINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FASTED |
|
311 ng/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6375.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2571627/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
CETIRIZINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2571627/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
CETIRIZINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FASTED |
|
8.3 h |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7% |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CETIRIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
180 mg single, oral Overdose |
unhealthy, 18 months |
|
270 mg single, oral Overdose |
unhealthy, 18 years |
Other AEs: Metabolic acidosis, Hypokalemia... Other AEs: Metabolic acidosis (grade 5, 1 patient) Sources: Hypokalemia (grade 5, 1 patient) |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 18 years |
Disc. AE: Delusions, Depression... AEs leading to discontinuation/dose reduction: Delusions (1 patient) Sources: Depression (1 patient) |
2.5 mg 1 times / day multiple, oral Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: |
unhealthy, 23 months Health Status: unhealthy Age Group: 23 months Sex: M Sources: |
Disc. AE: Insomnia... AEs leading to discontinuation/dose reduction: Insomnia (1 patient) Sources: |
10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
Other AEs: Dyspepsia, Feeling hot... Other AEs: Dyspepsia (1%) Sources: Feeling hot (1%) Dysgeusia (1%) Headache (1%) Paresthesia (1%) Presyncope (1%) Hyperhidrosis (1%) |
60 mg single, oral Overdose |
healthy, 4 years |
Other AEs: Drowsiness, Sedation... Other AEs: Drowsiness (severe, 1 patient) Sources: Sedation (1 patient) |
50 mg 1 times / day multiple, oral Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 46 years |
|
5 mg 1 times / day multiple, oral Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 6 years |
Disc. AE: Dystonic reaction... AEs leading to discontinuation/dose reduction: Dystonic reaction (1 patient) Sources: |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: |
Other AEs: Somnolence, Fatigue... Other AEs: Somnolence (13.7%) Sources: Fatigue (5.9%) Dry mouth (5%) Dizziness (2%) Pharyngitis (2%) |
0.24 % 2 times / day multiple, ophthalmic Recommended Dose: 0.24 %, 2 times / day Route: ophthalmic Route: multiple Dose: 0.24 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Ocular hyperemia, Visual acuity reduced... Other AEs: Ocular hyperemia (2%) Sources: Visual acuity reduced (0.6%) Conjunctival hyperemia (5.3%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hypokalemia | grade 5, 1 patient | 270 mg single, oral Overdose |
unhealthy, 18 years |
| Metabolic acidosis | grade 5, 1 patient | 270 mg single, oral Overdose |
unhealthy, 18 years |
| Delusions | 1 patient Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 18 years |
| Depression | 1 patient Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 18 years |
| Insomnia | 1 patient Disc. AE |
2.5 mg 1 times / day multiple, oral Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: |
unhealthy, 23 months Health Status: unhealthy Age Group: 23 months Sex: M Sources: |
| Dysgeusia | 1% | 10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
| Dyspepsia | 1% | 10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
| Feeling hot | 1% | 10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
| Headache | 1% | 10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
| Hyperhidrosis | 1% | 10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
| Paresthesia | 1% | 10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
| Presyncope | 1% | 10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M+F Sources: |
| Sedation | 1 patient | 60 mg single, oral Overdose |
healthy, 4 years |
| Drowsiness | severe, 1 patient | 60 mg single, oral Overdose |
healthy, 4 years |
| Dystonic reaction | 1 patient Disc. AE |
5 mg 1 times / day multiple, oral Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 6 years |
| Somnolence | 13.7% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: |
| Dizziness | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: |
| Pharyngitis | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: |
| Dry mouth | 5% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: |
| Fatigue | 5.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: |
| Visual acuity reduced | 0.6% | 0.24 % 2 times / day multiple, ophthalmic Recommended Dose: 0.24 %, 2 times / day Route: ophthalmic Route: multiple Dose: 0.24 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Ocular hyperemia | 2% | 0.24 % 2 times / day multiple, ophthalmic Recommended Dose: 0.24 %, 2 times / day Route: ophthalmic Route: multiple Dose: 0.24 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Conjunctival hyperemia | 5.3% | 0.24 % 2 times / day multiple, ophthalmic Recommended Dose: 0.24 %, 2 times / day Route: ophthalmic Route: multiple Dose: 0.24 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. | 2002-07-01 |
|
| Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. | 2002-07 |
|
| Extractionless and sensitive method for high-throughput quantitation of cetirizine in human plasma samples by liquid chromatography-tandem mass spectrometry. | 2002-06-25 |
|
| Antihistamines and the torsade de point in children with allergic rhinitis. | 2002-06-18 |
|
| Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. | 2002-06 |
|
| Treating seasonal allergic rhinitis. Trial does not show that there is no difference between butterbur and cetirizine. | 2002-05-25 |
|
| Treating seasonal allergic rhinitis. Well designed experiments should have been used. | 2002-05-25 |
|
| Applications of derivative UV spectrophotometry for the determinations of cetirizine dihydrochloride in pharmaceutical preparations. | 2002-05-25 |
|
| Gateways to clinical trials. | 2002-05-01 |
|
| Gateways to clinical trials. | 2002-05 |
|
| Urticarial intolerance reaction to cetirizine. | 2002-05 |
|
| Development and validation of a HPLC method for the determination of cetirizine in pharmaceutical dosage forms. | 2002-05 |
|
| [The first case of lasting pigmented toxidermia induced by cetirizine (Zyrtec, Virlix) and ticlopidine]. | 2002-04 |
|
| Major role for the carboxylic function of cetirizine and levocetirizine in their binding characteristics to human H1-histamine-receptors. | 2002-04 |
|
| Binding characteristics of [3H]levocetirizine to cloned human H1-histamine-receptors expressed in CHO cells. | 2002-04 |
|
| Acute hepatitis associated with cetirizine intake. | 2002-04 |
|
| Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. | 2002-04 |
|
| Cetirizine decreases interleukin-4, interleukin-5, and interferon-gamma gene expressions in nasal-associated lymphoid tissue of sensitized mice. | 2002-03-16 |
|
| [Already allergic to pollen in early childhood. Can future asthma still be prevented?]. | 2002-03-07 |
|
| [Skin prick test results in snoring and sleep apnea patients]. | 2002-03 |
|
| Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. | 2002-03 |
|
| Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. | 2002-03 |
|
| Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h. | 2002-03 |
|
| Cardiotoxicity of new antihistamines and cisapride. | 2002-02-28 |
|
| Are antihistamines useful in managing asthma? | 2002-02 |
|
| A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. | 2002-02 |
|
| Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). | 2002-02 |
|
| Serum tryptase in allergic rhinitis: effect of cetirizine and fluticasone propionate treatment. | 2002-01-25 |
|
| [Efficacy and safety of fexofenadine and cetirizine in the treatment of allergic rhinitis]. | 2002-01-23 |
|
| Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. | 2002-01-19 |
|
| Titrimetric and spectrophotometric assay of some antihistamines through the determination of the chloride of their hydrochlorides. | 2002-01 |
|
| Potential cardiac toxicity of H1-antihistamines. | 2002 |
|
| Pharmacokinetics of cetirizine in tear fluid after a single oral dose. | 2002 |
|
| Photosensitivity disorders: cause, effect and management. | 2002 |
|
| [Comparative antihistamine and anti-allergic effects of various antihistamine preparations]. | 2002 |
|
| Displacement of histamine from liver cells and cell components by ligands for cytochromes P450. | 2002 |
|
| Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells. | 2002 |
|
| [The allergic pregnant woman]. | 2001-12 |
|
| Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. | 2001-12 |
|
| A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. | 2001-12 |
|
| Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells by some second-generation H(1) receptor antagonists through blockade of store-operated Ca(2+) channels (SOCs). | 2001-11-01 |
|
| Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. | 2001-11 |
|
| Multiwavelength spectrophotometric resolution of the micro-equilibria of cetirizine. | 2001-10 |
|
| Preclinical comparison of ebastine and other second generation H1-antihistamines. | 2001-10 |
|
| Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. | 2001-10 |
|
| Antiallergic/antiasthmatic effect of novel antiallergic hexapeptide-95/220 in various experimental models. | 2001-09 |
|
| The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. | 2001 |
|
| Efficacy and safety of levocetirizine in seasonal allergic rhinitis. | 2001 |
|
| Cetirizine/pseudoephedrine. | 2001 |
|
| Impact of rhinitis on airway inflammation: biological and therapeutic implications. | 2001 |
Sample Use Guides
1 to 2 tablets once daily depending upon severity of symptoms; do not take more than 2 tablets in 24 hours
Route of Administration:
Oral
Cetirizine (10 micrograms/ml) significantly enhanced IL-1 release by human monocytes stimulated by a weak LPS concentration (1 microgram/ml) but could not modify the maximal increase of IL-1 release induced by 10 micrograms/ml of LPS. It did not exert any effect on resting cells. Cetirizine (0.1-10 micrograms/ml) enhanced PGE2 release by resting human monocytes. Concentrations of 1 and 10 micrograms/ml enhanced PGE2 release by LPS-stimulated monocytes, and by healthy and inflamed rat macrophages.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:49:09 GMT 2025
by
admin
on
Mon Mar 31 18:49:09 GMT 2025
|
| Record UNII |
64O047KTOA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
203150
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB11803MIG
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
64O047KTOA
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
DTXSID2044268
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
1102929
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
100000091468
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
X-17
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
m3291
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | Merck Index | ||
|
83881-52-1
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
C28920
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
55182
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
64O047KTOA
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
DBSALT001214
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
759102
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY | |||
|
CHEMBL1000
Created by
admin on Mon Mar 31 18:49:09 GMT 2025 , Edited by admin on Mon Mar 31 18:49:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
|
PARENT -> SALT/SOLVATE |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of content, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of content, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of content, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of content, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
![Structure of 2-[2-[2-[4-[(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]ethoxy]acetic acid](/img/ab8ffc0a-3e0e-493b-92ef-911e5a7049b4.svg "Structure of 2-[2-[2-[4-[(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]ethoxy]acetic acid")
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|